Vaxil Bio Ltd VXLLF:OTCPK

*Data is delayed | Exchange | USD
Last | 04/18/24 EDT
0.0053UNCH (UNCH)
52 week range
0.00 - 0.06
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.0053
  • 52 Week High0.06
  • 52 Week High Date08/23/23
  • 52 Week Low0.00
  • 52 Week Low Date12/18/23

Key Stats

  • Market Cap1.49M
  • Shares Out136.98M
  • 10 Day Average Volume54,300.25
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-73.5

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.0053
  • 52 Week High0.06
  • 52 Week High Date08/23/23
  • 52 Week Low0.00
  • 52 Week Low Date12/18/23
  • Market Cap1.49M
  • Shares Out136.98M
  • 10 Day Average Volume54,300.25
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-73.5

RATIOS/PROFITABILITY

  • EPS (TTM)-0.00
  • P/E (TTM)-2.18
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Vaxil Bio Ltd

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In...
Gadi Levin
Chairman of the Board, Chief Executive Officer
Alan Rootenberg
Chief Financial Officer
Address
3400 One First Canadian Place,
Toronto, ON
M5X 1A4
Canada